MedPath

Role of Heparin in Poor Responders Undergoing In Vitro Fertilisation

Phase 2
Completed
Conditions
Infertility
Interventions
Drug: Heparin, Low-Molecular-Weight
Registration Number
NCT01315093
Lead Sponsor
National and Kapodistrian University of Athens
Brief Summary

The addition of heparin increases pregnancy outcome parameters in poor responders undergoing In Vitro Fertilisation (IVF)

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • poor responders (age>40, abnormal ovarian test, </=4 oocytes in previous cycle with conventional stimulation)
  • infertility, indication for IVF
  • no contraindications for heparin
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Non Heparin, Low-Molecular-Weight groupno heparinIVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
Heparin, Low-Molecular-Weight groupHeparin, Low-Molecular-WeightLMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
Primary Outcome Measures
NameTimeMethod
no of oocytes retrievedegg recovery, 2 years

\>2 between groups

Secondary Outcome Measures
NameTimeMethod
miscarriage rate2 years

pregnancy loss \<20 weeks

clinical pregnancy rate2 years

Presence of fetal heart at transvaginal ultrasound at 6+2 gestational weeks

live birth rate2 years

\>20 weeks of gestation

cancellation ratebefore ET, 2 years

Trial Locations

Locations (1)

3rd Department of Obstetrics & Gynecology

🇬🇷

Athens, Chaidari, Greece

© Copyright 2025. All Rights Reserved by MedPath